--- title: Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent nct_id: NCT04936308 overall_status: ACTIVE_NOT_RECRUITING phase: PHASE3 sponsor: Janssen Research & Development, LLC study_type: INTERVENTIONAL primary_condition: Arthritis, Psoriatic countries: United States, Argentina, Australia, Bulgaria, Czechia, Hungary, Israel, Malaysia, Poland, Puerto Rico, Russia, Spain, Turkey (Türkiye), Ukraine canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04936308.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04936308" ct_last_update_post_date: 2026-05-08 last_seen_at: "2026-05-12T06:01:05.303Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent **Official Title:** A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent **NCT ID:** [NCT04936308](https://clinicaltrials.gov/study/NCT04936308) ## Key Facts - **Status:** ACTIVE_NOT_RECRUITING - **Phase:** PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 453 - **Lead Sponsor:** Janssen Research & Development, LLC - **Conditions:** Arthritis, Psoriatic - **Start Date:** 2021-09-28 - **Completion Date:** 2026-07-16 - **CT.gov Last Update:** 2026-05-08 ## Brief Summary The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA. ## Detailed Description PsA is a chronic, immune-mediated inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. Guselkumab is a fully human monoclonal antibody (mAb) that binds to p19 protein subunit of interleukin (IL)-23 and blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling, subsequent activation, and cytokine production. The primary hypothesis of this study is that guselkumab is superior to placebo as assessed by the proportion of participants who had an inadequate response (IR) and/or intolerance to one prior anti-tumor necrosis factor (anti-TNF) achieving an American College of Rheumatology 20 (ACR 20) response at Week 24. This study will consist of a screening phase (up to 6 weeks), blinded treatment phase (approximately up to 2 years), which includes a placebo-controlled period from Week 0 to Week 24, and an active-controlled treatment phase from Week 24 to Week 100, and safety follow-up phase (Week 112). Safety assessments will include physical examinations, vital signs, height, weight, electrocardiograms, and clinical safety laboratory assessments. The total duration of the study will be up to 118 weeks. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening * Have active PsA as defined by: at least 3 swollen joints and at least 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (\>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory * Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis * Have active plaque psoriasis, with at least one psoriatic plaque of \>= 2 centimeters (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis * Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as presence of active PsA despite previous treatment with one prior anti-TNF alpha agent Exclusion Criteria: * Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy in the treatment of PsA, including but not limited to rheumatoid arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic lupus erythematosus, or Lyme disease * Has received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (or biosimilars) * Has ever received Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor * Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention * Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients * Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (example, mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers ``` ## Arms - **Group 1: Guselkumab and Placebo** (EXPERIMENTAL) — Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. - **Group 2: Guselkumab** (EXPERIMENTAL) — Participants will receive guselkumab SC. - **Group 3: Placebo Followed by Guselkumab** (EXPERIMENTAL) — Participants will receive placebo SC and will cross over to receive guselkumab SC. ## Interventions - **Guselkumab** (DRUG) — Participants will receive guselkumab as SC injection. - **Placebo** (DRUG) — Participants will receive matching placebo as SC injection. ## Primary Outcomes - **Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24** _(time frame: At Week 24)_ — ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. ## Secondary Outcomes - **Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)** _(time frame: At Week 24)_ - **Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline** _(time frame: At Week 24)_ - **Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24** _(time frame: Baseline (pre dose Week 0) and Week 24)_ - **Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24** _(time frame: Baseline (pre dose Week 0) and Week 24)_ - **Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24** _(time frame: Baseline (pre dose Week 0) and Week 24)_ - **Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24** _(time frame: At Week 24)_ - **Percentage of Participants Who Achieved ACR 20 Response at Week 16** _(time frame: At Week 16)_ - **Percentage of Participants Who Achieved ACR 50 Response at Week 16** _(time frame: At Week 16)_ - **Percentage of Participants Who Achieved ACR 50 Response at Week 24** _(time frame: At Week 24)_ - **Percentage of Participants Who Achieved ACR 70 Response at Week 24** _(time frame: At Week 24)_ - **Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs)** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Percentage of Participants With Treatment Emergent Related AEs (TERAEs)** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Treatment Emergent AEs Leading to Discontinuation of Study Intervention** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Percentage of Participants With Infections** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Percentage of Participants With Injection-site Reactions** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Percentage of Participants With Infusion Related Reactions** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Number of Participants With Post-baseline Laboratory Abnormalities With Maximum Toxicity Grade Greater Than or Equal to >=3 Based on Common Terminology Criteria for Adverse Events (CTCAE)** _(time frame: From first administration of study drug (Week 0) up to Week 112)_ - **Serum Guselkumab Concentration Over Time** _(time frame: At Weeks 0, 4, 8, 12, 16, 20,and 24)_ - **Number of Participants With Antibodies to Guselkumab** _(time frame: Baseline (pre dose Week 0) up to Week 24)_ ## Locations (169) - Arthritis Associates, Mountain Brook, Alabama, United States - Arizona Arthritis and Rheumatology Research PLLC 2, Avondale, Arizona, United States - Arizona Arthritis and Rheumatology Research PLLC 3, Flagstaff, Arizona, United States - Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona, United States - Arizona Arthritis and Rheumatology Research PLLC 1, Phoenix, Arizona, United States - Arizona Arthritis and Rheumatology Associates, Sun City, Arizona, United States - Southern Arizona VA Healthcare System, Tucson, Arizona, United States - Unity Health-White County Medical Center, Searcy, Arkansas, United States - Newport Huntington Medical Group, Huntington Beach, California, United States - Medvin Clinical Research 2, Thousand Oaks, California, United States - Medvin Clinical Research, Tujunga, California, United States - Clinical Research Center of Connecticut, Danbury, Connecticut, United States - Bay Pines VA Healthcare System, Bay Pines, Florida, United States - Clinical Research of West Florida, Clearwater, Florida, United States - Omega Research Consultants, DeBary, Florida, United States - Advanced Clinical Research of Orlando, Ocoee, Florida, United States - Integral Rheumatology And Immunology Specialists, Plantation, Florida, United States - Clinical Research of West Florida 1, Tampa, Florida, United States - Florida Medical Clinic, P.A., Zephyrhills, Florida, United States - Great Lakes Clinical Trials, Chicago, Illinois, United States - Clinic of Robert Hozman, Skokie, Illinois, United States - The Arthritis and Diabetes Clinic, Monroe, Louisiana, United States - Johns Hopkins University, Baltimore, Maryland, United States - Klein And Associates M D P A, Hagerstown, Maryland, United States - Great Lakes Center of Rheumatology, Lansing, Michigan, United States - Arthritis and Rheumatology Center of MI, Okemos, Michigan, United States - Clinical Research Institute of Michigan, LLC, Saint Clair Shores, Michigan, United States - St. Paul Rheumatology P A, Eagan, Minnesota, United States - Arthritis Consultants, St Louis, Missouri, United States - Arthritis Rheumatic And Back Disease Associates, Voorhees Township, New Jersey, United States - Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States - Arthritis and Osteoperosis Associates of New Mexico, Las Cruces, New Mexico, United States - Buffalo Rheumatology and Medicine PLLC, Orchard Park, New York, United States - DJL Clinical Research, PLLC, Charlotte, North Carolina, United States - STAT Research, Inc., Vandalia, Ohio, United States - Health Research of Oklahoma, Oklahoma City, Oklahoma, United States - Rheumatology Associates of Oklahoma, Oklahoma City, Oklahoma, United States - Dr. Ramesh Gupta, Memphis, Tennessee, United States - Precision Comprehensive Clinical Research Solutions, Colleyville, Texas, United States - Adriana Pop Moody MD Clinic PA, Corpus Christi, Texas, United States - Metroplex Clinical Research Center, Dallas, Texas, United States - Precision Comprehensive Clinical Research Solutions 1, Fort Worth, Texas, United States - West Texas Clinical Research, Lubbock, Texas, United States - Southwest Rheumatology Research LLC, Mesquite, Texas, United States - Texas Rheumatology Care, Plano, Texas, United States - Advanced Rheumatology of Houston, The Woodlands, Texas, United States - DM Clinical Research, Tomball, Texas, United States - Arthritis And Osteoporosis Clinic, Waco, Texas, United States - Arthritis Northwest PLLC 1, Spokane, Washington, United States - Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States - Cosultorios Reumatologógicos Pampa, Buenos Aires, Argentina - OMI, Buenos Aires, Argentina - CIPREC, Buenos Aires, Argentina - Centro Privado de Medicina Familiar, Buenos Aires, Argentina - Hospital Central Militar Cirujano Mayor Dr Cosme Argerich, Buenos Aires, Argentina - Instituto de Reumatología Mendoza, Mendoza, Argentina - Centro de Investigaciones Medicas Tucuman, San Miguel de Tucumán, Argentina - Southern Clinical Research, Hobart, Australia - Liverpool Hospital, Liverpool, Australia - Skin Health Institute Inc., Melbourne, Australia - Eastern Health - Box Hill Hospital, Melbourne, Australia - UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria - Medical Center Unimed Plovdiv, Plovdiv, Bulgaria - UMHAT Kaspela, Plovdiv, Bulgaria - Diagnosis-consulting centre-1, Rousse, Bulgaria - Military Medical Academy, Sofia, Bulgaria - UMHAT St. Ivan Rilski, Sofia, Bulgaria - ASIMP Rheumatology Centre St Irina EOOD, Sofia, Bulgaria - University Multiprofile Hospital Sofiamed Sofia, Sofia, Bulgaria - Medical Centre Synexus, Sofia, Bulgaria - RHEUMA s r o, Břeclav, Czechia - L K N Arthrocentrum, Hlučín, Czechia - MUDr Rosypalova s r o, Ostrava, Czechia - Arthrohelp S.R.O., Pardubice, Czechia - Revmatologicky ustav, Prague, Czechia - Medical Plus S R O, Uherské Hradiště, Czechia - PV Medical S R O, Zlín, Czechia - Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz, Budapest, Hungary - Uno Medical Trials Ltd., Budapest, Hungary - Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház, Debrecen, Hungary - Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula, Hungary - Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary - Szegedi Tudományegyetem, ÁOK, Szent-Györgyi Albert Klinikai Központ, Szeged, Hungary - Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz, Székesfehérvár, Hungary - Vital Medical Center Orvosi es Fogaszati Kozpont, Veszprém, Hungary - Bnai Zion Medical Center, Haifa, Israel - Rambam Health Care Campus, Haifa, Israel - Carmel Medical Center, Haifa, Israel - Meir Medical Center, Kfar Saba, Israel - Sheba Medical Center, Ramat Gan, Israel - Hospital Selayang, Batu Caves, Malaysia - Hospital Pulau Pinang, George Town, Malaysia - Hospital Raja Permaisuri Bainun, Ipoh, Malaysia - Hospital Tuanku Jaafar, Seremban, Malaysia - Nzoz Bif Med, Bytom, Poland - Centrum Kliniczno Badawcze, Elblag, Poland - Malopolskie Badania Kliniczne Sp z o o, Krakow, Poland - Malopolskie Centrum Kliniczne, Krakow, Poland - Centrum Medyczne Promed, Krakow, Poland - Dermed Centrum Medyczne Sp z o o, Lodz, Poland - Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna, Lodz, Poland - NZOZ Lecznica MAK MED S C, Nadarzyn, Poland - Twoja Przychodnia - Centrum Medyczne Nowa Sol, Nowa Sól, Poland - Twoja Przychodnia PCM, Poznan, Poland - Centrum Medyczne, Poznan, Poland - Lubelskie Centrum Diagnostyczne, Świdnik, Poland - MICS Centrum Medyczne Warszawa, Warsaw, Poland - Rheuma Medicus Sp z o o, Warsaw, Poland - Centrum Medyczne Reuma Park, Warsaw, Poland - WroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland - GCM Medical Group, San Juan, Puerto Rico - Mindful Medical Research, San Juan, Puerto Rico - FDI Clinical Research, San Juan, Puerto Rico - Altay Medical State University, Barnaul, Russia - Chelyabinck Regional Clinical Hospital, Chelyabinsk, Russia - Chelyabinsk Regional Clinical Dermatovenerological Dispensary, Chelyabinsk, Russia - Kemerovo State Medical University, Kemerovo, Russia - LLL Medical Center Revma-Med, Kemerovo, Russia - LLC Family Outpatient Clinic # 4, Korolyov, Russia - Krasnodar Clinical Dermatovenerologic Dispensary, Krasnodar, Russia - Regional SBI of PH Krasnoyarsk Regional Clinical hospital #20 named after I.S. Berzon, Krasnoyarsk, Russia - Clinical-Diagnostic Center Euromedservice, JSC, Moscow, Russia - FGBU Research Institute of Rheumatology named V.A.Nasonova, Moscow, Russia - GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi', Moscow, Russia - GBOU VPO Orenburg State Medical University, Orenburg, Russia - Rostov Regional Clinical Dermatovenerological Dispensary, Rostov-on-Don, Russia - St. Petersburg GBUZ Clinical Reumatological Hospital 25, Saint Petersburg, Russia - X7 Clinical Research Company Limited, Saint Petersburg, Russia - Saratov Regional Clinical Hospital, Saratov, Russia - Smolensk regional hospital on Smolensk railway station, Smolensk, Russia - GBUZ of Samara Region 'Tolyatti City Clinical Hospital 5', Tolyatti, Russia - Tula Regional Clinical Dermatovenerological Dispensary, Tula, Russia - Republican Clinical Hospital - G.G. Kuvatov, Ufa, Russia - Hosp. Univ. de Cruces, Barakaldo, Spain - Hosp. Univ. de La Princesa, Madrid, Spain - Hosp. Quiron Madrid Pozuelo, Madrid, Spain - Hosp Regional Univ de Malaga, Málaga, Spain - Clinica Gaias, Santiago de Compostela, Spain - Hosp. Quiron Sagrado Corazon, Seville, Spain - Hosp. Clinico Univ. de Valencia, Valencia, Spain - Adana City Hospital, Adana, Turkey (Türkiye) - Gulhane Egitim ve Arastirma Hastanesi, Ankara, Turkey (Türkiye) - Ankara Bilkent City Hospital, Ankara, Turkey (Türkiye) - Hacettepe University Medical Faculty, Ankara, Turkey (Türkiye) - Akdeniz Universitesi Hastanesi, Antalya, Turkey (Türkiye) - Bursa Uludag Universitesi Hastanesi, Bursa, Turkey (Türkiye) - Pamukkale University Medical Faculty, Denizli, Turkey (Türkiye) - Osmangazi University Medical Faculty, Eskişehir, Turkey (Türkiye) - Istanbul University Istanbul Medical Faculty, Istanbul, Turkey (Türkiye) - Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey (Türkiye) - Kartal Dr Lutfi Kirdar sehir Hastanesi, Istanbul, Turkey (Türkiye) - Marmara University Medical Faculty, Istanbul, Turkey (Türkiye) - Kocaeli University Medical Faculty, Kocaeli, Turkey (Türkiye) - Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi, Konya, Turkey (Türkiye) - Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council, Cherkasy, Ukraine - Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital, Kharkiv, Ukraine - Khmelnitckiy regional hospital, Khmelnytsky, Ukraine - City Clinical Hospital No. 2, Kryvyi Rih, Ukraine - Medical Center LLC 'Harmony of Beauty', Kyiv, Ukraine - Medical Center of 'Institute of Rheumatology', LLC, Kyiv, Ukraine - Kyiv City Clinical Hospital #3, Kyiv, Ukraine - Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway', Kyiv, Ukraine - SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine, Kyiv, Ukraine - Medical Center 'Consylium Medical', Kyiv, Ukraine - Volyn Regional Clinical Hospital, Lutsk, Ukraine - LLC Medical House, Odesa, Ukraine - ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil, Poltava, Ukraine - Vinnitsia Regional Clinical Hospital n.a. M. I. Pyrogov, Vinnytsia, Ukraine - Medical Center LLC 'Modern Clinic', Zaporizhzhya, Ukraine ## Recent Field Changes (last 30 days) - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.arthritis associates|mountain brook|alabama|united states` — added _(2026-05-12)_ - `locations.arizona arthritis and rheumatology research pllc 2|avondale|arizona|united states` — added _(2026-05-12)_ - `locations.arizona arthritis and rheumatology research pllc 3|flagstaff|arizona|united states` — added _(2026-05-12)_ - `locations.arizona arthritis and rheumatology research pllc|mesa|arizona|united states` — added _(2026-05-12)_ - `locations.arizona arthritis and rheumatology research pllc 1|phoenix|arizona|united states` — added _(2026-05-12)_ - `locations.arizona arthritis and rheumatology associates|sun city|arizona|united states` — added _(2026-05-12)_ - `locations.southern arizona va healthcare system|tucson|arizona|united states` — added _(2026-05-12)_ - `locations.unity health-white county medical center|searcy|arkansas|united states` — added _(2026-05-12)_ - `locations.newport huntington medical group|huntington beach|california|united states` — added _(2026-05-12)_ - `locations.medvin clinical research 2|thousand oaks|california|united states` — added _(2026-05-12)_ - `locations.medvin clinical research|tujunga|california|united states` — added _(2026-05-12)_ - `locations.clinical research center of connecticut|danbury|connecticut|united states` — added _(2026-05-12)_ - `locations.bay pines va healthcare system|bay pines|florida|united states` — added _(2026-05-12)_ - `locations.clinical research of west florida|clearwater|florida|united states` — added _(2026-05-12)_ - `locations.omega research consultants|debary|florida|united states` — added _(2026-05-12)_ - `locations.advanced clinical research of orlando|ocoee|florida|united states` — added _(2026-05-12)_ - `locations.integral rheumatology and immunology specialists|plantation|florida|united states` — added _(2026-05-12)_ - `locations.clinical research of west florida 1|tampa|florida|united states` — added _(2026-05-12)_ - `locations.florida medical clinic, p.a.|zephyrhills|florida|united states` — added _(2026-05-12)_ - `locations.great lakes clinical trials|chicago|illinois|united states` — added _(2026-05-12)_ - `locations.clinic of robert hozman|skokie|illinois|united states` — added _(2026-05-12)_ - `locations.the arthritis and diabetes clinic|monroe|louisiana|united states` — added _(2026-05-12)_ - `locations.johns hopkins university|baltimore|maryland|united states` — added _(2026-05-12)_ - `locations.klein and associates m d p a|hagerstown|maryland|united states` — added _(2026-05-12)_ - `locations.great lakes center of rheumatology|lansing|michigan|united states` — added _(2026-05-12)_ - `locations.arthritis and rheumatology center of mi|okemos|michigan|united states` — added _(2026-05-12)_ - `locations.clinical research institute of michigan, llc|saint clair shores|michigan|united states` — added _(2026-05-12)_ - `locations.st. paul rheumatology p a|eagan|minnesota|united states` — added _(2026-05-12)_ - `locations.arthritis consultants|st louis|missouri|united states` — added _(2026-05-12)_ - `locations.arthritis rheumatic and back disease associates|voorhees township|new jersey|united states` — added _(2026-05-12)_ - `locations.albuquerque center for rheumatology|albuquerque|new mexico|united states` — added _(2026-05-12)_ - `locations.arthritis and osteoperosis associates of new mexico|las cruces|new mexico|united states` — added _(2026-05-12)_ - `locations.buffalo rheumatology and medicine pllc|orchard park|new york|united states` — added _(2026-05-12)_ - `locations.djl clinical research, pllc|charlotte|north carolina|united states` — added _(2026-05-12)_ - `locations.stat research, inc.|vandalia|ohio|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04936308.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04936308* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*